The bolus thrombolytic agent, tenecteplase, narrowly failed to show non-inferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients with acute ischemic stroke.
"It therefore lends considerable weight to the previous evidence showing non-inferiority of tenecteplase to alteplase, with the updated meta-analysis now suggesting superiority," he added. The primary outcome was the proportion of patients without disability at 3 months. Safety outcomes were all-cause mortality and symptomatic intracranial hemorrhage.
He pointed out that as tenecteplase is administered via a single bolus injection, it is easier and quicker to administer than alteplase, which is given as a bolus plus an infusion, thus saving time in the urgent treatment of patients with acute stroke.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: MSNBC - 🏆 469. / 51 Read more »
Source: MSNBC - 🏆 469. / 51 Read more »
Source: MSNBC - 🏆 469. / 51 Read more »
Source: CBSNews - 🏆 87. / 68 Read more »
Source: FoxNews - 🏆 9. / 87 Read more »
Texas AG Paxton to Newsmax: Attended Trump's Trial to Show SupportRepublican Texas Attorney General Ken Paxton told Newsmax he attended former President Donald Trump's criminal trial in New York on Tuesday as an act of solidarity.
Source: NEWSMAX - 🏆 16. / 71 Read more »